Results 301 to 310 of about 356,633 (356)

Cohesin haploinsufficiency is tolerated in Cbfb::MYH11-driven murine acute myeloid leukemia. [PDF]

Exp Hematol
Conneely SE, Quezada A, Kurtz KJ, Zhang N, Fuente J, Mercer N, Rogers JH, Aguilar R, Medrano G, Goodell MA, Liu PP, Pati D, Rau RE.   +12 more
europepmc   +1 more source

Outcomes of patients with relapsed/refractory acute leukaemia treated with revumenib with a focus on post‐revumenib therapies

British Journal of Haematology, EarlyView.
Miles Thomas, Hannah Johnston, Emily Dworkin, Austin Wesevich, Gregory W. Roloff, Caner Saygin, Mariam T. Nawas, Michael W. Drazer, Adam S. DuVall, Satyajit Kosuri, Michael J. Thirman, Olatoyosi Odenike, Wendy Stock, Richard A. Larson, Rafael Madero‐Marroquin, Anand A. Patel   +15 more
wiley   +1 more source

Deep Learning links TP53 genotype to expression-defined transcriptional program in Acute Myeloid Leukemia

Tsesmelis M, Andersson R, Perez AF, Vazquez SM, Carolina Florian M, Mulaw MA.   +5 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Venetoclax in acute myeloid leukemia

Expert Opinion on Investigational Drugs, 2023
Background: Substantial progress in the therapeutic arsenal used to treat acute myeloid leukemia became possible in the last decade, as a result of advances in gene editing and descriptive and functional genomics. Objective: The aim of this study is to analyze the efficacy and safety of venetoclax in the treatment of acute myeloid leukemia ...
Bruzzese, Antonella, Martino, Enrica Antonia, Mendicino, Francesco, Lucia, Eugenio, Olivito, Virginia, Neri, Antonino, Morabito, Fortunato, Vigna, Ernesto, Gentile, Massimo   +8 more
openaire   +4 more sources

Acute Myeloid Leukemia

Journal of the National Comprehensive Cancer Network, 2008
Approximately 13,290 people will be diagnosed with acute myeloid leukemia (AML) in 2008, and 8820 patients will die of the disease. As the population ages, the incidence of AML, along with myelodysplasia, appears to be rising. Clinical trials have led to significant treatment improvements in some areas, primarily acute promyelocytic leukemia.
Margaret R, O'Donnell, Frederick R, Appelbaum, Steven E, Coutre, Lloyd E, Damon, Harry P, Erba, James, Foran, Jeffrey, Lancet, Lori J, Maness, Guido, Marcucci, Peter G, Maslak, Michael, Millenson, Joseph O, Moore, Farhad, Ravandi, Friedrich, Schuening, Paul, Shami, B Douglas, Smith, Richard M, Stone, Martin S, Tallman, Eunice, Wang, Frank L, White   +19 more
openaire   +5 more sources

Acute Myeloid Leukemia

Hematology, 2001
AbstractThrough the hard work of a large number of investigators, the biology of acute myeloid leukemia (AML) is becoming increasingly well understood, and as a consequence, new therapeutic targets have been identified and new model systems have been developed for testing novel therapies.
F R, Appelbaum, J M, Rowe, J, Radich, J E, Dick   +3 more
openaire   +2 more sources

Acute Myeloid Leukemia

Hematology/Oncology Clinics of North America, 2009
The evolution of acute myeloid leukemia (AML) classification reflects greater understanding of the AML pathogenesis. The 2008 World Health Organization classification incorporated cytogenetic and molecular genetic findings and introduced important prognostic correlations.
Amy, Heerema-McKenney, Daniel A, Arber
openaire   +2 more sources

Acute Myeloid Leukemia

Hematology, 2002
AbstractIn this chapter, Drs. Keating and Willman review recent advances in our understanding of the pathophysiology of acute myeloid leukemia (AML) and allied conditions, including the advanced myelodysplastic syndromes (MDS), while Drs. Goldstone, Avivi, Giles, and Kantarjian focus on therapeutic data with an emphasis on current patient care and ...
Francis J, Giles, Armand, Keating, Anthony H, Goldstone, Irit, Avivi, Cheryl L, Willman, Hagop M, Kantarjian   +5 more
openaire   +2 more sources

Immunotherapy for Acute Myeloid Leukemia

Seminars in Hematology, 2015
Despite longstanding efforts in basic research and clinical studies, the prognosis for patients with acute myeloid leukemia (AML) remains poor. About half of the patients are not medically fit for intensive induction therapy to induce a complete remission and are treated with palliative treatment concepts.
Lichtenegger, F.S., Krupka, C., Köhnke, T., Subklewe, M.   +3 more
openaire   +3 more sources